Genentech, Inc. and Biogen Idec, Inc. received approval from the FDA for two additional uses for Rituxan for patients with CD20-positive, B-cell non-Hodgkin’s lymphoma (NHL). One new indication is for first-line treatment of previously untreated patients with follicular NHL in combination with CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy. The second is for the treatment of low-grade NHL in patients with stable disease or who achieve a partial or complete response follo...